Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
ConditionThymic Carcinoma
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFudan University
About this trial
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are:
1. Does adjuvant chemotherapy decrease disease progression? 2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance?
Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not.
Participants will:
1. Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF). 2. Follow up every 3 months in the first two year, and then every 6 months.
Eligibility criteria
Qualifiers
Voluntarily participate and sign an informed consent form in writing;
Age range from 18 to 75 years old, regardless of gender;
Within 3 months after the surgery is completed;
Histologically diagnosed with thymic cancer;
Disqualifiers
Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical carcinoma in situ, or other curable tumors that have been tumor free for more than 3 years after treatment);
Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness;
Pregnancy and lactation period;
Patients with drug addiction, chronic alcoholism and AIDS;
Trial design
Treatments tested in this trial
- Chemotherapy
- Radiotherapy
Treatment groups
172 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov